Proteins

Product Data Sheet

IRBP (1-20), human

Cat. No.: HY-P1587 CAS No.: 298202-25-2 Molecular Formula: $C_{101}H_{164}N_{24}O_{28}S$

2194.59 Molecular Weight:

Sequence: Gly-Pro-Thr-His-Leu-Phe-Gln-Pro-Ser-Leu-Val-Leu-Asp-Met-Ala-Lys-Val-Leu-Leu-Asp


Sequence Shortening: **GPTHLFQPSLVLDMAKVLLD**

Others Target: Others Pathway:

Storage: Sealed storage, away from moisture

> Powder -80°C 2 years

-20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (45.57 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|-----------|-----------|
| | 1 mM | 0.4557 mL | 2.2783 mL | 4.5567 mL |
| | 5 mM | 0.0911 mL | 0.4557 mL | 0.9113 mL |
| | 10 mM | 0.0456 mL | 0.2278 mL | 0.4557 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (1.14 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (1.14 mM); Clear solution

BIOLOGICAL ACTIVITY

IRBP (1-20), human contains a major epitope for the H-2^b haplotype. IRBP (1-20), human induces experimental autoimmune Description uveoretinitis (EAU) in H-2^b mice^{[1][2]}.

In Vivo IRBP (1-20), human TFA induces EAU^[2].

> For determination of proliferative and cytokine responses, lymph node and spleen cells are collected 21 days after immunization and are stimulated in culture with the appropriate antigen. Cells of C57BL/6 mice and 129/J mice immunized with IRBP (1-20), human TFA proliferated in response to the peptide^[2].

^{*} In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

| MCE has not independe | ently confirmed the accuracy of these methods. They are for reference only. | |
|-----------------------|--|--|
| Animal Model: | C57BL/6 (H-2 ^{bb} [2] | |
| Dosage: | 200, 300 μg | |
| Administration: | I.h.; After 21 days | |
| Result: | C57BL/6 (H-2 ^{bb}) also developed disease, albeit with a lower average score than C57BL/6. | |

REFERENCES

[1]. Avichezer D, et al. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice. Exp Eye Res. 2000;71(2):111-118.

[2]. Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci. 2000;41(1):127-131.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA